ArticleCureus2025
Continuous Glucose Monitoring With Linx™ Improves Glycemic Control and Satisfaction in Youth With Type 1 Diabetes: A Real-World Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren and adolescents with type 1 diabetes (T1D) often have poor glycemic control and low satisfaction with management tools, increasing risks of complications. This study evaluated the clinical efficacy and user satisfaction of a novel real-time continuous glucose monitoring (CGM) system, Linx™ (Microtech Medical (Hangzhou) Co., Ltd., Zhejiang, China), over three months in adolescents with poorly controlled T1D.
methodsIn this single-center, single-arm, observational study, 75 children and adolescents using multiple daily injections were enrolled. Clinical outcomes (HbA1c, insulin dose, and hypoglycemia) and CGM metrics (time in range, glucose variability, and calculated Glycemia Risk Index) were assessed at baseline, 28, and 90 days. Patient satisfaction was measured at three months using the validated 44-item CGM Satisfaction (CGM-SAT) questionnaire.
resultsAfter three months of continuous Linx™ CGM use, median HbA1c significantly decreased from 9.5% to 8.1% (absolute reduction of 1.4 percentage points; p<0.001). Time in range (%TIR
conclusionsThe Linx™ 15-day CGM system led to marked improvements in glycemic control and safety, along with high satisfaction, in children and adolescents with poorly controlled T1D. These results support the value of factory-calibrated CGM devices in optimizing diabetes management and quality of life in this vulnerable group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.